SEC Form 4 · accession 0001209191-17-013751
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Schenkein
Officer — Chief Executive Officer · Director
Period of report
Feb 21, 2017
Accepted (ET)
Feb 23, 2017 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $50.40 | Feb 21, 2017 | A | 142,900 | A | — | Feb 20, 2027 | Common stock | 142,900 | 142,900 | D |
Explanation of responses
- F1This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.